REG - BioPharma Credit PLC - NEW INVESTMENT OF US$30 MILLION

Biopharma CreditAnnouncement

07/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251007:nRSG2838Ca&default-theme=true

RNS Number : 2838C  BioPharma Credit PLC  07 October 2025

7 October 2025

 

BIOPHARMA CREDIT PLC

(THE "COMPANY")

NEW INVESTMENT OF US$30 MILLION

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt
investment trust, is pleased to announce that it, through its fully owned
subsidiary, together with BioPharma Credit Investments V (Master)
LP ("BioPharma-V" and jointly with the Company, the "Lenders") has entered
into a senior secured loan agreement with Valneva Austria GmbH, a subsidiary
of Valneva SE ("Valneva"). The initial tranche is expected to be funded in the
coming weeks, with the Company investing US$30 million, BioPharma-V investing
an additional US$185 million in parallel, and the Company acting as
collateral agent. Further tranches of up to US$285 million for potential
business development are subject to mutual agreement by the parties with loan
allocations to be determined at such time.

Based in Saint-Herblain, France, Valneva is a specialty vaccine company with a
current market capitalization of approximately US$1 billion that develops,
manufactures, and commercializes prophylactic vaccines for infectious diseases
addressing unmet medical needs. Valneva currently markets prophylactic
vaccines IXIARO (Japanese Encephalitis), DUKORAL (Cholera) and IXCHIQ
(Chikungunya).

The loan will mature in October 2030 and will bear interest at 9.00 per cent.
per annum.

Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP, the Company's
investment adviser said:

"We are proud to continue our partnership with Valneva. This transaction marks
the third investment in Valneva made by entities managed by Pharmakon
Advisors. BioPharma III invested US$30 million in 2013, and an additional
US$11 million in 2015. This transaction reflects our great confidence in
Valneva's products, strategy, management team, and execution capabilities. At
Pharmakon, we remain committed to supporting high-quality life sciences
companies with tailored capital solutions."

 

Enquiries

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

Notes to Editors

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. The Company seeks to
provide long-term shareholder returns, principally in the form of sustainable
income distributions from exposure to the life sciences industry. The Company
seeks to achieve this objective primarily through investments in debt assets
secured by royalties or other cash flows derived from the sales of approved
life sciences products.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUNAARVNURRUA